NASDAQ:IMTX Immatics - IMTX Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Immatics Please log in to your account or sign up in order to add this asset to your watchlist. $8.73 +0.03 (+0.34%) (As of 02/7/2023 04:08 PM ET) Add Compare Share Share Today's Range$8.55▼$8.8150-Day Range$7.81▼$11.3652-Week Range$5.75▼$13.60Volume173,421 shsAverage Volume229,701 shsMarket Capitalization$665.49 millionP/E Ratio13.03Dividend YieldN/APrice Target$27.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Immatics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside209.6% Upside$27.00 Price TargetShort InterestBearish4.91% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.00Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom $0.59 to ($1.45) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.73 out of 5 starsMedical Sector811th out of 1,029 stocksBiological Products, Except Diagnostic Industry130th out of 168 stocks 3.5 Analyst's Opinion Consensus RatingImmatics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $27.00, Immatics has a forecasted upside of 209.6% from its current price of $8.72.Amount of Analyst CoverageImmatics has received no research coverage in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted4.91% of the float of Immatics has been sold short.Short Interest Ratio / Days to CoverImmatics has a short interest ratio ("days to cover") of 17.4, which indicates bearish sentiment.Change versus previous monthShort interest in Immatics has recently decreased by 2.40%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldImmatics does not currently pay a dividend.Dividend GrowthImmatics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for IMTX. Previous Next 0.6 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 3 news articles for Immatics this week, compared to 0 articles on an average week.Search InterestOnly 2 people have searched for IMTX on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.MarketBeat Follows2 people have added Immatics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Immatics insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 29.05% of the stock of Immatics is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Immatics are expected to decrease in the coming year, from $0.59 to ($1.45) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Immatics is 13.02, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 140.18.Price to Earnings Ratio vs. SectorThe P/E ratio of Immatics is 13.02, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 115.80.Price to Book Value per Share RatioImmatics has a P/B Ratio of 19.38. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Immatics (NASDAQ:IMTX) StockImmatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its ACTengine product candidates are in Phase I clinical trials, which include IMA201 that targets melanoma-associated antigen 4 or 8 in patients with solid tumors; IMA202 that targets melanoma-associated antigen 1 in patients with various solid tumors, including squamous non-small cell lung carcinoma and hepatocellular carcinoma; and IMA203 that targets preferentially expressed antigen in melanoma in adult patients with relapsed and/or refractory solid tumors, as well as IMA204, which is in preclinical studies that targets tumor stroma cell. The company's TCR Bispecifics product candidates, which are in preclinical studies include IMA401, a cancer testis antigen for the treatment of solid tumors; and IMA402 for the treatment of solid tumors. It also develops IMA101 for the treatment of cancer; and IMA301, an allogenic cellular therapy product candidate. The company has a strategic collaboration agreement with GlaxoSmithKline Intellectual Property Development Limited to develop novel adoptive cell therapies targeting multiple cancer indications; MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Switzerland LLC to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.Read More Receive IMTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Immatics and its competitors with MarketBeat's FREE daily newsletter. Email Address IMTX Stock News HeadlinesFebruary 6, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Neurocrine (NBIX) and Immatics (IMTX)February 1, 2023 | americanbankingnews.comImmatics (NASDAQ:IMTX) Sees Large Volume IncreaseFebruary 7, 2023 | Wall Street Watch Dogs (Ad)The #1 Energy Stock to BuyThe next major energy revolution is unfolding right now. And it could hand early investors as much as 46,700% gains…December 17, 2022 | finance.yahoo.comImmatics N.V.'s (NASDAQ:IMTX) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?December 16, 2022 | reuters.comIMTX.O - Immatics NV | Stock Price & Latest News | ReutersNovember 17, 2022 | finance.yahoo.comImmatics Announces Third Quarter 2022 Financial Results and Business UpdateNovember 17, 2022 | finance.yahoo.comImmatics (IMTX) Reports Q3 Loss, Tops Revenue EstimatesOctober 31, 2022 | finance.yahoo.comDoes Immatics (IMTX) Have the Potential to Rally 77% as Wall Street Analysts Expect?February 7, 2023 | Wall Street Watch Dogs (Ad)The #1 Energy Stock to BuyThe next major energy revolution is unfolding right now. And it could hand early investors as much as 46,700% gains…October 14, 2022 | msn.comWall Street Analysts See an 81% Upside in Immatics (IMTX): Can the Stock Really Move This High?October 10, 2022 | nz.finance.yahoo.comShareholders in Immatics (NASDAQ:IMTX) are in the red if they invested a year agoOctober 10, 2022 | seekingalpha.comHot Stocks: Macau stocks drop on COVID worries; EDU, TAL plunge; AXNX downgrade; IMTX rises on clinical dataOctober 10, 2022 | msn.comImmatics Immunotherapy Candidate Shows Confirmed Responses In Different Solid CancersOctober 10, 2022 | finance.yahoo.comImmatics Reports Interim Clinical Data Update on ACTengine® IMA203 TCR-T Monotherapy Targeting PRAMEOctober 10, 2022 | finance.yahoo.comImmatics Announces $110 Million Underwritten Offering of Ordinary SharesSeptember 27, 2022 | seekingalpha.comIMTX Immatics N.V.September 13, 2022 | nasdaq.comFurther weakness as Immatics (NASDAQ:IMTX) drops 11% this week, taking one-year losses to 26%August 29, 2022 | reuters.comIMTX.OQ - Immatics NV | Stock Price & Latest News | ReutersAugust 24, 2022 | finanznachrichten.deImmatics Announces First Cancer Patient Treated with Second-Generation ACTengine TCR-T Candidate IMA203CD8 Targeting PRAMEAugust 23, 2022 | finance.yahoo.comImmatics Announces First Cancer Patient Treated with Second-Generation ACTengine® TCR-T Candidate IMA203CD8 Targeting PRAMEAugust 12, 2022 | finance.yahoo.comWall Street Analysts Think Immatics (IMTX) Could Surge 82%: Read This Before Placing a BetAugust 9, 2022 | nz.finance.yahoo.comImmatics Announces Second Quarter 2022 Financial Results and Business UpdateJuly 20, 2022 | nasdaq.comStrength Seen in Immatics (IMTX): Can Its 18% Jump Turn into More Strength?June 25, 2022 | finance.yahoo.comDo Its Financials Have Any Role To Play In Driving Immatics N.V.'s (NASDAQ:IMTX) Stock Up Recently?June 17, 2022 | morningstar.comImmatics NV Ordinary Shares - Stock ChartJune 9, 2022 | seekingalpha.comEditas in licensing deal with Immatics for cancer therapiesJune 2, 2022 | seekingalpha.comImmatics GAAP EPS of €1.35, revenue of €102.91MSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive IMTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Immatics and its competitors with MarketBeat's FREE daily newsletter. Email Address IMTX Company Calendar Last Earnings11/17/2022Today2/07/2023Next Earnings (Estimated)3/22/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:IMTX CUSIPN/A CIK1809196 Webwww.immatics.com Phone49-7071-539-7700FaxN/AEmployees188Year FoundedN/APrice Target and Rating Average Stock Price Forecast$27.00 High Stock Price Forecast$28.00 Low Stock Price Forecast$26.00 Forecasted Upside/Downside+209.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)$0.67 Trailing P/E Ratio13.03 Forward P/E Ratio14.80 P/E GrowthN/ANet Income$-110,430,000.00 Net Margins24.60% Pretax Margin22.98% Return on Equity40.49% Return on Assets12.91% Debt Debt-to-Equity RatioN/A Current Ratio2.60 Quick Ratio2.60 Sales & Book Value Annual Sales$41.13 million Price / Sales16.18 Cash FlowN/A Price / Cash FlowN/A Book Value$0.45 per share Price / Book19.40Miscellaneous Outstanding Shares76,230,000Free FloatN/AMarket Cap$665.49 million OptionableNot Optionable Beta0.49 Key ExecutivesDr. Harpreet Singh Ph.D. (Age 47)CEO, MD, Member of Management Board & Supervisory Director Dr. Hans-Georg Rammensee Ph.D.Co-Founder & Member of the Scientific Advisory BoardDr. Toni Weinschenk Ph.D. (Age 49)Co-Founder & Chief Innovation Officer Mr. Arnd Christ MBA (Age 56)Chief Financial Officer Mr. Steffen Walter Ph.D. (Age 46)Chief Technology Officer Mr. Edward A. SturchioGen. Counsel & Sec.Ms. Anja Heuer B.Sc.Director of Corp. CommunicationsMs. Tamara Louw M.B.A.P.H.R., Sr. Director of HRDr. Carsten Reinhardt M.D. (Age 55)Ph.D., Chief Devel. Officer Dr. Rainer Kramer Ph.D. (Age 57)Chief Bus. Officer & Site Head Munich More ExecutivesKey CompetitorsScholar RockNASDAQ:SRRKFate TherapeuticsNASDAQ:FATEPoseida TherapeuticsNASDAQ:PSTXHilleVaxNASDAQ:HLVXCoherus BioSciencesNASDAQ:CHRSView All CompetitorsInsiders & InstitutionsPlatinum Investment Management Ltd.Sold 75,236 shares on 11/15/2022Ownership: 0.337%Marshall Wace LLPBought 83,631 shares on 11/15/2022Ownership: 0.124%Two Sigma Investments LPBought 39,503 shares on 11/15/2022Ownership: 0.052%Two Sigma Advisers LPBought 18,600 shares on 11/15/2022Ownership: 0.024%BlackRock Inc.Sold 6,947 shares on 11/15/2022Ownership: 0.009%View All Institutional Transactions IMTX Stock - Frequently Asked Questions Should I buy or sell Immatics stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Immatics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" IMTX shares. View IMTX analyst ratings or view top-rated stocks. What is Immatics' stock price forecast for 2023? 2 Wall Street analysts have issued twelve-month price targets for Immatics' shares. Their IMTX share price forecasts range from $26.00 to $28.00. On average, they predict the company's stock price to reach $27.00 in the next year. This suggests a possible upside of 210.3% from the stock's current price. View analysts price targets for IMTX or view top-rated stocks among Wall Street analysts. How have IMTX shares performed in 2023? Immatics' stock was trading at $8.71 at the start of the year. Since then, IMTX shares have decreased by 0.1% and is now trading at $8.70. View the best growth stocks for 2023 here. When is Immatics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 22nd 2023. View our IMTX earnings forecast. How were Immatics' earnings last quarter? Immatics (NASDAQ:IMTX) announced its quarterly earnings data on Thursday, November, 17th. The company reported ($0.32) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.31) by $0.01. The firm had revenue of $15.18 million for the quarter, compared to analysts' expectations of $13.36 million. Immatics had a net margin of 24.60% and a trailing twelve-month return on equity of 40.49%. What other stocks do shareholders of Immatics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Immatics investors own include Advanced Micro Devices (AMD), Ampio Pharmaceuticals (AMPE), Chimerix (CMRX), Datadog (DDOG), Forte Biosciences (FBRX), Great Panther Mining (GPL), Idera Pharmaceuticals (IDRA) and Immunic (IMUX). What is Immatics' stock symbol? Immatics trades on the NASDAQ under the ticker symbol "IMTX." How do I buy shares of Immatics? Shares of IMTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Immatics' stock price today? One share of IMTX stock can currently be purchased for approximately $8.70. How much money does Immatics make? Immatics (NASDAQ:IMTX) has a market capitalization of $663.20 million and generates $41.13 million in revenue each year. The company earns $-110,430,000.00 in net income (profit) each year or $0.67 on an earnings per share basis. How many employees does Immatics have? The company employs 188 workers across the globe. How can I contact Immatics? Immatics' mailing address is 51 ASTOR PLACE 10TH FLOOR, NEW YORK NY, 10003. The official website for the company is www.immatics.com. The company can be reached via phone at 49-7071-539-7700. This page (NASDAQ:IMTX) was last updated on 2/7/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.